BioSig Technologies, Inc. (NASDAQ:BSGM) has said its flagship PURE EP System technology will be featured in a live patient case streamed during the 16th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy (VT 2021), held virtually on October 15-16, 2021.
VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias. The event is hosted by the Department of Medicine, Division of Cardiology, University of Pennsylvania Health System in Philadelphia, Pennsylvania and the Division of Cardiology, The Mount Sinai Hospital in New York, New York.
In a statement, Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies said: “Treatments for ventricular arrhythmias have historically been complex due to the very challenging nature of these conditions. We are focusing on uncovering important additional physiologic information to hopefully improve the ventricular arrhythmia treatments, and we are thrilled to be included in the live case coverage during this year’s VT Symposium that is solely focused on complex cardiac arrhythmias. We want to thank the course directors and the global faculty for opening this important educational event to all stakeholders and look forward to the two days of insightful sessions."
READ: BioSig says clinical data acquired by its PURE EP System published in Journal of Cardiovascular Electrophysiology
To date, over 70 physicians have completed over 1500 patient cases with BioSig's PURE EP System across thirteen clinical sites. Clinical data acquired by the PURE EP System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library.
Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals
The company's first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact the author at jon.hopkins@proactiveinvestors.com